These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18580450)

  • 1. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
    Woltering EA; Salvo VA; O'Dorisio TM; Lyons J; Li G; Zhou Y; Seward JR; Go VL; Vinik AI; Mamikunian P; Mamikunian G
    Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.
    Woltering EA; Mamikunian PM; Zietz S; Krutzik SR; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2005 Nov; 31(4):392-400. PubMed ID: 16258376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF; Hager DF
    Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract]   [Full Text] [Related]  

  • 4. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.
    Joseph S; Li G; Lindholm E; Zhou Y; Go VL; Vinik AI; O'Dorisio TM; Mamikunian G; Woltering EA
    Pancreas; 2010 Oct; 39(7):964-6. PubMed ID: 20467346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Al-Efraij K; Aljama MA; Kennecke HF
    Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
    Dogliotti L; Tampellini M; Stivanello M; Gorzegno G; Fabiani L
    Ann Oncol; 2001; 12 Suppl 2():S105-9. PubMed ID: 11762334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
    Falconi M; Fazio N; Ferone D; Versari A
    Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
    Garland J; Buscombe JR; Bouvier C; Bouloux P; Chapman MH; Chow AC; Reynolds N; Caplin ME
    Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.